Les-6666
Les-6666 is a β-tubulin inhibitor. Les-6666 exerts antiproliferative, pro-apoptotic, cell cycle arrest and migration-inhibitory effects, and suppresses DNA synthesis. Les-6666 can be used in the research of pancreatic cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C19H14N2O3S
- 分子量:350.39
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
β-Tubulin |
体外実験
Les-6666 potently inhibits the growth of the NCI-60 human tumor cell line panel with a mean GI50 of 0.056 μM, and shows particularly strong activity against K-562, SR, NCI-H522, and MDA-MB-435 cell lines[1].
Les-6666 (0.001-10 μM; 24-72 h) exhibits potent cytotoxicity against multiple cancer cell lines, with the strongest activity against MIA PaCa-2 pancreatic cancer cells (IC50 = 0.08 μM at 72 h), and shows lower toxicity against normal Beas-2B and HDFa cells[1].
Les-6666 (0.1-1 μM; 48 h) inhibits DNA synthesis and proliferation of MIA PaCa-2 pancreatic cancer cells, reducing [3H]-thymidine incorporation to 35-44% of control levels after 48 h of treatment at 0.1-1 μM[1].
Les-6666 (0.1-1 μM; 48 h) potently suppresses clonogenic survival of MIA PaCa-2 pancreatic cancer cells, reducing the surviving fraction to less than 3% after 48 h of treatment at 0.1-1 μM[1].
Les-6666 (0.1-0.5 μM; 24-48 h) strongly inhibits migration of MIA PaCa-2 pancreatic cancer cells, limiting gap closure to 4.7-10.7% after 24-48 h of treatment at 0.1-0.5 μM[1].
Les-6666 (0.1-0.5 μM; 48 h) induces significant early and late apoptosis in MIA PaCa-2 pancreatic cancer cells, with combined apoptotic populations reaching over 74% after 48 h of treatment at 0.1-0.5 μM[1].
Les-6666 (0.1-0.5 μM; 48 h) arrests MIA PaCa-2 pancreatic cancer cells in the G2/M phase of the cell cycle, increasing the G2/M population to over 33% after 48 h of treatment at 0.1-0.5 μM[1].
Les-6666 (0.1-0.5 μM; 48 h) reduces β-tubulin protein concentration in MIA PaCa-2 pancreatic cancer cells, lowering levels to ~50% of control after 48 h of treatment at 0.1-0.5 μM[1].
Les-6666 (0.1-0.5 μM; 48 h) reduces βIII-tubulin protein expression in MIA PaCa-2 pancreatic cancer cells, lowering levels to 71.7-78.7% of control after 48 h of treatment at 0.1-0.5 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:pancreatic cancer MIA PaCa-2, Capan-2, Panc-1; breast cancer MDA-MB-231, MCF-7, HCC-1954; colon cancer HT-29; gastric cancer AGS; liver cancer HepG2; glioblastoma T98G, U87, A172; lung cancer A549, H1299; normal transformed HDFa, Beas-2B cells
-
Concentration:0.001,
0.01, 0.1, 1, 10 μM -
Incubation Time:24 h, 48 h, 72 h
-
Result:After 72 h, the IC50 values were 0.08 μM (MIA PaCa-2), 0.71 μM (Capan-2), 5.76 μM (Panc-1), 1.26 μM (HCC-1954), 0.86 μM (HT-29), 1.82 μM (T98G), 0.45 μM (A549), > 10 μM (MDA-MB-231, MCF-7, AGS, HepG2, U87, A172, H1299), > 10 μM (HDFa), and 1.10 μM (Beas-2B).
After 24 h, the IC50 for MIA PaCa-2 was 5.73 μM; after 48 h, it was 0.48 μM.
The IC50 for Beas-2B after 48 h was 3.89 μM, and no measurable IC50 was observed for HDFa after 48 h.
-
Cell Line:pancreatic cancer MIA PaCa-2 cells
-
Concentration:0.1, 0.5 and 1 μM
-
Incubation Time:48 h
-
Result:At 0.1 μM, [3H]-thymidine incorporation was 41.00% relative to control; at 0.5 μM, it was 44.33% relative to control; at 1 μM, it was 35.00% relative to control.
-
Cell Line:pancreatic cancer MIA PaCa-2 cells
-
Concentration:0.1, 0.5 and 1 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:After 48 h of treatment at all tested concentrations, the surviving fraction was reduced to less than 3% relative to control.
-
Cell Line:pancreatic cancer MIA PaCa-2 cells
-
Concentration:0.1, 0.5 and 1 μM
-
Incubation Time:24 h, 48 h
-
Result:At 24 h, gap closure was 4.7% (0.5 μM) and 6.3% (0.1 μM) relative to 40% in control; at 48 h, gap closure was 8.3% (0.5 μM) and 10.7% (0.1 μM) relative to 57% in control.
-
Cell Line:pancreatic cancer MIA PaCa-2 cells
-
Concentration:0.1, 0.5 and 1 μM
-
Incubation Time:48 h
-
Result:At 0.1 μM, early apoptosis was 20.40% and late apoptosis was 54.37% relative to 4.37% early and 15.67% late apoptosis in control; at 0.5 μM, early apoptosis was 20.93% and late apoptosis was 53.43% relative to control.
-
Cell Line:pancreatic cancer MIA PaCa-2 cells
-
Concentration:0.1, 0.5 and 1 μM
-
Incubation Time:48 h
-
Result:At both 0.1 μM and 0.5 μM, over 33% of cells were arrested in the G2/M phase, compared to 22.17% in control.
-
Cell Line:pancreatic cancer MIA PaCa-2 cells
-
Concentration:0.1, 0.5 and 1 μM
-
Incubation Time:48 h
-
Result:At 0.1 μM, β-tubulin concentration was 648.3 pg/mL; at 0.5 μM, it was 640.4 pg/mL, compared to 1289.0 pg/mL in control.
-
Cell Line:pancreatic cancer MIA PaCa-2 cells
-
Concentration:0.1, 0.5 and 1 μM
-
Incubation Time:48 h
-
Result:At 0.1 μM, relative βIII-tubulin expression was 78.7% of control; at 0.5 μM, it was 71.7% of control.
化学情報
-
分子量 350.39
-
分子式 C19H14N2O3S
-
SMILES
OC(C=C1)=CC=C1NC(S/2)=NC(C2=C\C3=CC=CC=C3OCC#C)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)